Sopharma AD Statistics
Total Valuation
Sopharma AD has a market cap or net worth of PLN 4.01 billion. The enterprise value is 5.38 billion.
| Market Cap | 4.01B |
| Enterprise Value | 5.38B |
Important Dates
The last earnings date was Monday, March 2, 2026.
| Earnings Date | Mar 2, 2026 |
| Ex-Dividend Date | Dec 18, 2025 |
Share Statistics
| Current Share Class | 519.26M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -46.99% |
| Shares Change (QoQ) | +3.23% |
| Owned by Insiders (%) | 9.78% |
| Owned by Institutions (%) | 0.29% |
| Float | 166.10M |
Valuation Ratios
The trailing PE ratio is 14.81.
| PE Ratio | 14.81 |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| PB Ratio | 1.87 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 99.52 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.36, with an EV/FCF ratio of -102.97.
| EV / Earnings | 19.88 |
| EV / Sales | 0.98 |
| EV / EBITDA | 10.36 |
| EV / EBIT | 15.08 |
| EV / FCF | -102.97 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.64.
| Current Ratio | 1.31 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 3.24 |
| Debt / FCF | -26.40 |
| Interest Coverage | 6.22 |
Financial Efficiency
Return on equity (ROE) is 14.42% and return on invested capital (ROIC) is 6.88%.
| Return on Equity (ROE) | 14.42% |
| Return on Assets (ROA) | 4.19% |
| Return on Invested Capital (ROIC) | 6.88% |
| Return on Capital Employed (ROCE) | 9.83% |
| Weighted Average Cost of Capital (WACC) | 4.05% |
| Revenue Per Employee | 927,114 |
| Profits Per Employee | 45,858 |
| Employee Count | 5,905 |
| Asset Turnover | 1.40 |
| Inventory Turnover | 4.34 |
Taxes
In the past 12 months, Sopharma AD has paid 37.67 million in taxes.
| Income Tax | 37.67M |
| Effective Tax Rate | 11.62% |
Stock Price Statistics
The stock price has increased by +89.21% in the last 52 weeks. The beta is 0.05, so Sopharma AD's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | +89.21% |
| 50-Day Moving Average | 7.18 |
| 200-Day Moving Average | 5.06 |
| Relative Strength Index (RSI) | 44.99 |
| Average Volume (20 Days) | 1,299 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sopharma AD had revenue of PLN 5.47 billion and earned 270.79 million in profits. Earnings per share was 0.97.
| Revenue | 5.47B |
| Gross Profit | 1.26B |
| Operating Income | 262.98M |
| Pretax Income | 324.29M |
| Net Income | 270.79M |
| EBITDA | 380.20M |
| EBIT | 262.98M |
| Earnings Per Share (EPS) | 0.97 |
Balance Sheet
The company has 71.20 million in cash and 1.38 billion in debt, giving a net cash position of -1.31 billion.
| Cash & Cash Equivalents | 71.20M |
| Total Debt | 1.38B |
| Net Cash | -1.31B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.14B |
| Book Value Per Share | 4.00 |
| Working Capital | 535.55M |
Cash Flow
In the last 12 months, operating cash flow was 40.31 million and capital expenditures -92.58 million, giving a free cash flow of -52.28 million.
| Operating Cash Flow | 40.31M |
| Capital Expenditures | -92.58M |
| Free Cash Flow | -52.28M |
| FCF Per Share | n/a |
Margins
Gross margin is 22.94%, with operating and profit margins of 4.80% and 4.95%.
| Gross Margin | 22.94% |
| Operating Margin | 4.80% |
| Pretax Margin | 5.92% |
| Profit Margin | 4.95% |
| EBITDA Margin | 6.94% |
| EBIT Margin | 4.80% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.36, which amounts to a dividend yield of 5.12%.
| Dividend Per Share | 0.36 |
| Dividend Yield | 5.12% |
| Dividend Growth (YoY) | 200.38% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 20.91% |
| Buyback Yield | 46.99% |
| Shareholder Yield | 52.11% |
| Earnings Yield | 6.75% |
| FCF Yield | -1.30% |
Stock Splits
The last stock split was on July 10, 2025. It was a forward split with a ratio of 3.
| Last Split Date | Jul 10, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Sopharma AD has an Altman Z-Score of 2.49 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.49 |
| Piotroski F-Score | 5 |